Comparative evaluation of cell types for endothelialization in cardiovascular tissue engineering

Articles in Press

Document Type : Review Article

Authors

1 Basic Medical Sciences Program, School of Health and Medical Sciences, Libyan International University, Benghazi, Libya

2 Division of Medical Education, School of Medical Sciences, University of Manchester, Manchester, United Kingdom

3 Program of Medicine, School of Health and Medical Sciences, Libyan International University, Benghazi, Libya

4 Department of Pathology, Medical Center, Libyan International University, Benghazi, Libya

10.22038/ijbms.2026.93080.20132

Abstract

Tissue engineering represents a promising approach to overcome the limitations of current vascular grafts by promoting endothelialization. However, the successful fabrication of small-diameter (<6 mm) tissue-engineered vascular grafts (TEVGs) that maintain the desired mechanical strength, biocompatibility, and long-term patency of native vessels remains a significant challenge. The development of an ideal TEVG depends largely on achieving complete endothelial coverage using appropriate autologous cells that can mimic the functional properties of native endothelium. Several studies have highlighted various autologous and stem cell sources with potential for graft endothelialization, including endothelial progenitor cells (EPCs), embryonic stem cells (ESCs), human umbilical vein endothelial cells (HUVECs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). Despite extensive preclinical progress, the most suitable cell source for generating stable and functional endothelium in small-diameter TEVGs remains unclear, representing a key gap in current knowledge. This review therefore evaluates the principal cell types investigated in cardiovascular tissue engineering, outlining their main advantages, limitations, and translational potential. Overall, a critical comparison of these cell sources highlights the need for further research to determine their long-term safety, durability, and suitability for clinical application in the construction of functional and durable TEVGs.

Keywords

Main Subjects

References

1. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012; 110: 1097-1108.
2. Hinton W, McGovern A, Coyle R, Han TS, Sharma P, Correa A, et al. Incidence and prevalence of cardiovascular disease in English primary care: A cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open 2018; 8: e020282.
3. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res 2019; 124: 315-327.
4. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment. Neth Heart J 2017; 25: 231-242.
5. McKavanagh P, Yanagawa B, Zawadowski G, Cheema A. Management and prevention of saphenous vein graft failure: A review. Cardiol Ther 2017; 6: 203-223.
6. Gaudino M, Antoniades C, Benedetto U, Deb S, Franco AD, Giammarco GD, et al. Mechanisms, consequences, and prevention of coronary graft failure. Circulation 2017; 136: 1749-1764.
7. Wan S, George SJ, Berry C, Baker AH. Vein graft failure: Current clinical practice and potential for gene therapeutics. Gene Ther 2012; 19: 630-636.
8. Melchiorri AJ, Hibino N, Fisher JP. Strategies and techniques to enhance the in situ endothelialization of small-diameter biodegradable polymeric vascular grafts. Tissue Eng Part B Rev 2013; 19: 292-307.
9. Wang K, Lin RZ, Melero-Martin JM. Bioengineering human vascular networks: Trends and directions in endothelial and perivascular cell sources. Cell Mol Life Sci 2019; 76: 421-439.
10. Medina-Leyte DJ, Domínguez-Pérez M, Mercado I, Villarreal-Molina MT, Jacobo-Albavera L. Use of human umbilical vein endothelial cells (HUVEC) as a model to study cardiovascular disease: A review. Appl Sci 2020; 10: 938.
11. Naito Y, Shinoka T, Duncan D, Hibino N, Solomon D, Cleary M, et al. Vascular tissue engineering: Towards the next generation vascular grafts. Adv Drug Deliv Rev 2011; 63: 312-323.
12. Carrabba M, Madeddu P. Current strategies for the manufacture of small size tissue engineering vascular grafts. Front Bioeng Biotechnol 2018; 6: 41.
13. Soares JS, Saunders SK, Potere F, Toldo S, Abbate A. Engineered tissue vascular grafts: Are we there yet? Appl Eng Sci 2022; 12: 100114.
14. Luo J, Qin L, Zhao L, Gui L, Ellis MW, Huang Y, et al. Readily available tissue-engineered vascular grafts derived from human induced pluripotent stem cells. Circ Res 2022; 130: 925-927.
15. Park J, Riaz M, Qin L, Zhang W, Batty L, Fooladi S, et al. Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency. Cell Stem Cell 2025; 32: 137-143.
16. Smith RJ Jr, Nasiri B, Kann J, Yergeau D, Bard JE, Swartz DD, et al. Endothelialization of arterial vascular grafts by circulating monocytes. Nat Commun 2020; 11: 1622.
17. Tang Y, Yin L, Gao S, Long X, Du Z, Zhou Y, et al. A small-diameter vascular graft immobilized peptides for capturing endothelial colony-forming cells. Front Bioeng Biotechnol 2023; 11: 1154986.
18. Alasvand N, Behnamghader A, Milan PB, Simorgh S, Mobasheri A, Mozafari M. Tissue-engineered small-diameter vascular grafts containing novel copper-doped bioactive glass biomaterials to promote angiogenic activity and endothelial regeneration. Mater Today Bio 2023; 20: 100647.
19. Tian Y, Seeto WJ, Páez-Arias MA, Hahn MS, Lipke EA. Endothelial colony forming cell rolling and adhesion supported by peptide-grafted hydrogels. Acta Biomater 2022; 152: 74-85.
20. Abutaleb NO, Truskey GA. Differentiation and characterization of human iPSC-derived vascular endothelial cells under physiological shear stress. STAR Protoc 2021; 2: 100394.
21. Mahara A, Shirai M, Soni R, Le HT, Shimizu K, Hirano Y, et al. Vascular tissue reconstruction by monocyte subpopulations on small-diameter acellular grafts via integrin activation. Mater Today Bio 2023; 23: 100847.
22. Duan K, Dash BC, Sasson DC, Islam S, Parker J, Hsia HC. Human iPSC-derived vascular smooth muscle cells in a fibronectin functionalized collagen hydrogel augment endothelial cell morphogenesis. Bioengineering 2021; 8: 223. 
23. Kim FY, Marhefka G, Ruggiero NJ, Adams S, Whellan DJ. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev 2013; 21: 101-109.
24. Melchiorri AJ, Hibino N, Yi T, Lee YU, Sugiura T, Tara S, et al. Contrasting biofunctionalization strategies for the enhanced endothelialization of biodegradable vascular grafts. Biomacromolecules 2015; 16: 437-446.
25. Abbott WM, Callow A, Moore W, Rutherford R, Veith F, Weinberg S. Evaluation and performance standards for arterial prostheses. J Vasc Surg 1993; 17: 746-756.
26. Budd JS, Allen KE, Hartley G, Bell PR. The effect of preformed confluent endothelial cell monolayers on the patency and thrombogenicity of small calibre vascular grafts. Eur J Vasc Surg 1991; 5: 397-405.
27. Pasic M, Müller-Glauser W, von Segesser LK, Lachat M, Mihaljevic T, Turina M I. Superior late patency of small-diameter Dacron grafts seeded with omental microvascular cells: An experimental study. Ann Thorac Surg 1994; 58: 677-684.
28. Fukunishi T, Best CA, Ong CS, Groehl T, Reinhardt J, Yi T, et al. Role of bone marrow mononuclear cell seeding for nanofiber vascular grafts. Tissue Eng Part A 2018; 24: 135-144.
29. Wang S, Mo X, Jiang, Gao CJ, Wang HS, Zhuang YG, et al. Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency. Int J Nanomedicine 2013; 8: 2131-2139.
30. Meier LA, Syedain ZH, Lahti MT, Johnson SS, Chen MH, Hebbel RP, et al. Blood outgrowth endothelial cells alter remodeling of completely biological engineered grafts implanted into the sheep femoral artery. J Cardiovasc Trans Res 2014; 7: 242-249.
31. Lopes-Coelho F, Silva F, Gouveia-Fernandes S, Martins C, Lopes N, Domingues G, et al. Monocytes as endothelial progenitor cells (EPCs), another brick in the wall to disentangle tumor angiogenesis. Cells 2020; 9: 107.
32. Peters EB. Endothelial progenitor cells for the vascularization of engineered tissues. Tissue Eng Part B Rev 2018; 24: 1-24.
33. Richardson MR, Yoder MC. Endothelial progenitor cells: Quo Vadis? J Mol Cell Cardiol 2011; 50: 266-272.
34. Yuan J jing, Yang J, Sun S lei, Zhang R, Xu Y ming. Endothelial progenitor cells’ classification and application in neurological diseases. Tissue Eng Regen Med 2017; 14: 327-332.
35. Ladhoff J, Fleischer B, Hara Y, Volk HD, Seifert M. Immune privilege of endothelial cells differentiated from endothelial progenitor cells. Cardiovasc Res 2010; 88: 121-129.
36. Kaushal S, Amiel GE, Guleserian KJ, O M Shapira OM, Perry T, Sutherland FW, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001; 7: 1035-1040.
37. Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, et al. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2008; 111: 1302-1305.
38. Munisso MC, Yamaoka T. Circulating endothelial progenitor cells in small-diameter artificial blood vessel. J Artif Organs 2020; 23: 6-13.
39. Krawiec JT, Vorp DA. Adult stem cell-based tissue engineered blood vessels: A review. Biomaterials 2012; 33: 3388e3400.
40. Lynch K, Pei M. Age associated communication between cells and matrix: A potential impact on stem cell-based tissue regeneration strategies. Organogenesis 2014; 10: 289-298.
41. Lindenmair A, Hatlapatka T, Kollwig G, Hennerbichler S, Gabriel C, Wolbank S, et al. Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications. Cells 2012; 1: 1061-1088.
42. Warrier S, Haridas N, Bhonde R. Inherent propensity of amnion-derived mesenchymal stem cells towards endothelial lineage: Vascularization from an avascular tissue. Placenta 2012; 33: 850-858.
43. Faiella W, Atoui R. Therapeutic use of stem cells for cardiovascular disease. Clin Transl Med 2016; 5: 34.
44. Giuliani M, Bennaceur-Griscelli A, Nanbakhsh A, Oudrhiri N, Chouaib S, Azzarone B, et al. TLR ligands stimulation protects MSC from NK killing. Stem Cells 2014; 32: 290-300.
45. Ej Reinders M. NK cells and MSCs: Possible implications for MSC therapy in renal transplantation. J Stem Cell Res Ther 2014; 4: 1000166.
46. Wingate K, Bonani W, Tan Y, Bryant SJ, Tan W. Compressive elasticity of three-dimensional nanofiber matrix directs mesenchymal stem cell differentiation to vascular cells with endothelial or smooth muscle cell markers. Acta Biomater 2012; 8: 1440-1449.
47. Jouda H, Larrea Murillo L, Wang T. Current progress in vascular engineering and its clinical applications. Cells 2022; 11: 493.
48. Zhao Y, Zhang S, Zhou J, Wang J, Zhen M, Liu Y, et al. The development of a tissue-engineered artery using decellularized scaffold and autologous ovine mesenchymal stem cells. Biomaterials 2010; 31: 296-307.
49. Iacobazzi D, Swim MM, Albertario A, Caputo M, Ghorbel MT. Thymus-derived mesenchymal stem cells for tissue engineering clinical-grade cardiovascular grafts. Tissue Eng Part A 2018; 24: 794-808.
50. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant 2016; 25: 829-848.
51. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep 2015; 35: e00191.
52. Young RA. Control of the embryonic stem cell state. Cell 2011; 144: 940-954.
53. Wang Y, Yin P, Bian GL, Huang HY, Shen H, Yang JJ, et al. The combination of stem cells and tissue engineering: an advanced strategy for blood vessels regeneration and vascular disease treatment. Stem Cell Res Ther 2017; 8: 194.
54. Ferreira LS, Gerecht S, Shieh HF, Watson N, Rupnick MA, Dallabrida SM, et al. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle–like cells and form vascular networks in vivo. Circ Res 2007; 101: 286-294.
55. Hill KL, Obrtlikova P, Alvarez DF, King JA, Keirstead SA, Allred JR, et al. Human embryonic stem cell−derived vascular progenitor cells capable of endothelial and smooth muscle cell function. Exp Hematol 2010; 38: 246-257.
56. Kurtovic S, Ng TT, Gupta A, Arumugaswami V, Chaiboonma  KL, Aminzadeh MA, et al. Leptin enhances endothelial cell differentiation and angiogenesis in murine embryonic stem cells. Microvasc Res 2015; 97: 65-74.
57. Lee S, Valmikinathan CM, Byun J, Kim S, Lee G, Mokarram N, et al. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes. Biomaterials 2015; 63: 158-167.
58. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK. Transforming growth factor-β1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 2004; 287: C1560-C1568.
59. Park JK, Lee TW, Do EK, Moon HJ, Kim JH. Role of Notch1 in the arterial specification and angiogenic potential of mouse embryonic stem cell-derived endothelial cells. Stem Cell Res Ther 2018; 9: 197.
60. James D, Nam H song, Seandel M, Nolan D, Janovitz T, Tomishima M, et al. Expansion and maintenance of human embryonic stem cell–derived endothelial cells by TGFβ inhibition is Id1 dependent. Nat Biotechnol 2010; 28: 161-166.
61. Gong H, An S, Sassmann A, Liu M, Mastej V, Mittal M, et al. PAR1 scaffolds TGFβRII to downregulate TGF-β signaling and activate ESC differentiation to endothelial cells. Stem Cell Reports 2016; 7: 1050-1058.
62. Sun LT, Yamaguchi S, Hirano K, Ichisaka T, Kuroda T, Tada T. Nanog co-regulated by Nodal/Smad2 and Oct4 is required for pluripotency in developing mouse epiblast. Dev Biol 2014; 392: 182-192.
63. Vargel Ö, Zhang Y, Kosim K, Ganter K, Foehr S, Mardenborough Y, et al. Activation of the TGFβ pathway impairs endothelial to haematopoietic transition. Sci Rep 2016; 6: 21518.
64. Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007; 25: 317-318.
65. Lau S, Gossen M, Lendlein A, Jung F. Venous and arterial endothelial cells from human umbilical cords: Potential cell sources for cardiovascular research. Int J Mol Sci 2021; 22: 978.
66. Kocherova I, Bryja A, Mozdziak P, Volponi AA, Dyszkiewicz-KonwiĊ„ska M, Piotrowska-Kempisty H, et al. Human umbilical vein endothelial cells (HUVECs) co-culture with osteogenic cells: From molecular communication to engineering prevascularised bone grafts. J Clin Med 2019; 8: 1602.
67. Cai Q, Liao W, Xue F, Wang X, Zhou W, Li Y, et al. Selection of different endothelialization modes and different seed cells for tissue-engineered vascular graft. Bioact Mater 2021; 6: 2557-2568.
68. Kadner A, Zund G, Maurus C, Breymann C, Yakarisik S, Kadner G, et al. Human umbilical cord cells for cardiovascular tissue engineering: A comparative study. Eur J Cardiothorac Surg 2004; 25: 635-641.
69. Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-Honigmann MR, et al. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A 2000; 97: 9191-9196.
70. Mishra R, Roux BM, Posukonis M, Bodamer E, Brey EM, Fisher JP, et al. Effect of prevascularization on in vivo vascularization of poly(propylene fumarate)/fibrin scaffolds. Biomaterials 2016; 77: 255-266.
71. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012; 10: 16-28.
72. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
73. Patsch C, Challet-Meylan L, Thoma EC, Urich E, Heckel T, O’Sullivan JF, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol 2015; 17: 994-1003.
74. Nakayama KH, Joshi PA, Lai ES, Gujar P, Joubert LM, Chen B, et al. Bilayered vascular graft derived from human induced pluripotent stem cells with biomimetic structure and function. Regen Med 2015; 10: 745-755.
75. Kohler EE, Wary KK, Li F, Chatterjee I, Urao N, Toth PT, et al. Flk1+ and VE-cadherin+ endothelial cells derived from iPSCs recapitulates vascular development during differentiation and display similar angiogenic potential as ESC-derived cells. PLoS One 2013; 8: e85549.
76. Margariti A, Winkler B, Karamariti E, Zampetaki A, Tsai T, Baban D, et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci USA 2012; 109: 13793-13798.
77. Gui L, Dash BC, Luo J, Qin L, Zhao L, Yamamoto K,et al. Implantable tissue-engineered blood vessels from human induced pluripotent stem cells. Biomaterials 2016; 102: 120-129.
78. Luo J, Qin L, Zhao L, Gui L, Ellis MW, Huang Y, et al. Tissue engineered vascular grafts with advanced mechanical strength from human iPSCs. Cell Stem Cell 2020; 26: 251-261.
79. Galat V, Galat Y, Perepitchka M, Jennings LJ, Iannaccone PM, Hendrix MJC. Transgene reactivation in induced pluripotent stem cell derivatives and reversion to pluripotency of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Dev 2016; 25: 1060-1072.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 26 May 2026

Files

Share

How to cite

Statistics